Bionano Genomics

Historical price data

Bionano Genomics is a public company commercializing Optical Genome Mapping (OGM), a technology platform designed to detect structural variants (SVs) across the genome. The company has established a growing body of evidence with over 500 publications and is transitioning from research to clinical adoption, with its Stratys™ and Saphyr® systems targeting cytogenetics and molecular genomics labs. Its strategy focuses on positioning OGM as an essential, complementary tool to next-generation sequencing (NGS) to fill the critical 'structural variant gap' in comprehensive genomic analysis.

Optical Genome Mapping (OGM) technology that images long, linearized DNA molecules to detect structural variants (SVs) across the genome, providing a digital, high-resolution alternative to traditional cytogenetics and a complement to next-generation sequencing.

Bionano competes with traditional cytogenetics providers (e.g., Abbott), next-generation sequencing giants (Illumina, Thermo Fisher) as a complementary technology, and other long-read platforms (PacBio, Oxford Nanopore). Its defensibility relies on OGM's specific advantages for certain structural variants, a growing clinical evidence base, and integrated analysis software.